Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Apr 1;355(Pt 1):215–222. doi: 10.1042/0264-6021:3550215

Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.

M M Vilchis-Landeros 1, J L Montiel 1, V Mendoza 1, G Mendoza-Hernández 1, F López-Casillas 1
PMCID: PMC1221729  PMID: 11256966

Abstract

Betaglycan is an accessory receptor of members of the transforming growth factor-beta (TGF-beta) superfamily, which regulates their actions through ligand-dependent interactions with type II receptors. A natural soluble form of betaglycan is found in serum and extracellular matrices. Soluble betaglycan, prepared as a recombinant protein using the baculoviral expression system, inhibits the actions of TGF-beta. Because of its potential use as an anti-TGF-beta therapeutic agent, we have purified and characterized baculoviral recombinant soluble betaglycan. Baculoviral soluble betaglycan is a homodimer formed by two 110 kDa monomers associated by non-covalent interactions. This protein is devoid of glycosaminoglycan chains, although it contains the serine residues, which, in vertebrate cells, are modified by these carbohydrates. On the other hand, mannose-rich carbohydrates account for approximately 20 kDa of the mass of the monomer. End-terminal sequence analysis of the soluble betaglycan showed that Gly(24) is the first residue of the mature protein. Similarly to the natural soluble betaglycan, baculoviral soluble betaglycan has an equilibrium dissociation constant (K(d)) of 3.5 nM for TGF-beta1. Ligand competition assays indicate that the relative affinities of recombinant soluble betaglycan for the TGF-beta isoforms are TGF-beta2>TGF-beta3>TGF-beta1. The anti-TGF-beta potency of recombinant soluble betaglycan in vitro is 10-fold higher for TGF-beta2 than for TGF-beta1. Compared with a commercial pan-specific anti-TGF-beta neutralizing antibody, recombinant soluble betaglycan is more potent against TGF-beta2 and similar against TGF-beta1. These results indicate that baculoviral soluble betaglycan has the biochemical and functional properties that would make it a suitable agent for the treatment of the diseases in which excess TGF-beta plays a central physiopathological role.

Full Text

The Full Text of this article is available as a PDF (271.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ailor E., Betenbaugh M. J. Modifying secretion and post-translational processing in insect cells. Curr Opin Biotechnol. 1999 Apr;10(2):142–145. doi: 10.1016/s0958-1669(99)80024-x. [DOI] [PubMed] [Google Scholar]
  2. Andres J. L., Rönnstrand L., Cheifetz S., Massagué J. Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan. J Biol Chem. 1991 Dec 5;266(34):23282–23287. [PubMed] [Google Scholar]
  3. Andres J. L., Stanley K., Cheifetz S., Massagué J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J Cell Biol. 1989 Dec;109(6 Pt 1):3137–3145. doi: 10.1083/jcb.109.6.3137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Arribas J., López-Casillas F., Massagué J. Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding. J Biol Chem. 1997 Jul 4;272(27):17160–17165. doi: 10.1074/jbc.272.27.17160. [DOI] [PubMed] [Google Scholar]
  5. Attisano L., Wrana J. L., López-Casillas F., Massagué J. TGF-beta receptors and actions. Biochim Biophys Acta. 1994 May 26;1222(1):71–80. doi: 10.1016/0167-4889(94)90026-4. [DOI] [PubMed] [Google Scholar]
  6. Bissell D. M. Hepatic fibrosis as wound repair: a progress report. J Gastroenterol. 1998 Apr;33(2):295–302. doi: 10.1007/s005350050087. [DOI] [PubMed] [Google Scholar]
  7. Blobe G. C., Schiemann W. P., Lodish H. F. Role of transforming growth factor beta in human disease. N Engl J Med. 2000 May 4;342(18):1350–1358. doi: 10.1056/NEJM200005043421807. [DOI] [PubMed] [Google Scholar]
  8. Border W. A., Noble N. A. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 1997 May;51(5):1388–1396. doi: 10.1038/ki.1997.190. [DOI] [PubMed] [Google Scholar]
  9. Border W. A., Noble N. A., Yamamoto T., Harper J. R., Yamaguchi Y. u., Pierschbacher M. D., Ruoslahti E. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992 Nov 26;360(6402):361–364. doi: 10.1038/360361a0. [DOI] [PubMed] [Google Scholar]
  10. Border W. A., Okuda S., Languino L. R., Sporn M. B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990 Jul 26;346(6282):371–374. doi: 10.1038/346371a0. [DOI] [PubMed] [Google Scholar]
  11. Border W. A., Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest. 1992 Jul;90(1):1–7. doi: 10.1172/JCI115821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brown C. B., Boyer A. S., Runyan R. B., Barnett J. V. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science. 1999 Mar 26;283(5410):2080–2082. doi: 10.1126/science.283.5410.2080. [DOI] [PubMed] [Google Scholar]
  13. Böttinger E. P., Factor V. M., Tsang M. L., Weatherbee J. A., Kopp J. B., Qian S. W., Wakefield L. M., Roberts A. B., Thorgeirsson S. S., Sporn M. B. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5877–5882. doi: 10.1073/pnas.93.12.5877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cheifetz S., Hernandez H., Laiho M., ten Dijke P., Iwata K. K., Massagué J. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J Biol Chem. 1990 Nov 25;265(33):20533–20538. [PubMed] [Google Scholar]
  15. DAVIS B. J. DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS. Ann N Y Acad Sci. 1964 Dec 28;121:404–427. doi: 10.1111/j.1749-6632.1964.tb14213.x. [DOI] [PubMed] [Google Scholar]
  16. Evan G. I., Lewis G. K., Ramsay G., Bishop J. M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol. 1985 Dec;5(12):3610–3616. doi: 10.1128/mcb.5.12.3610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Henis Y. I., Moustakas A., Lin H. Y., Lodish H. F. The types II and III transforming growth factor-beta receptors form homo-oligomers. J Cell Biol. 1994 Jul;126(1):139–154. doi: 10.1083/jcb.126.1.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hildebrand A., Romarís M., Rasmussen L. M., Heinegård D., Twardzik D. R., Border W. A., Ruoslahti E. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J. 1994 Sep 1;302(Pt 2):527–534. doi: 10.1042/bj3020527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kaname S., Ruoslahti E. Betaglycan has multiple binding sites for transforming growth factor-beta 1. Biochem J. 1996 May 1;315(Pt 3):815–820. doi: 10.1042/bj3150815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kingsley D. M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994 Jan;8(2):133–146. doi: 10.1101/gad.8.2.133. [DOI] [PubMed] [Google Scholar]
  21. Kuroda K., Geyer H., Geyer R., Doerfler W., Klenk H. D. The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector. Virology. 1990 Feb;174(2):418–429. doi: 10.1016/0042-6822(90)90095-9. [DOI] [PubMed] [Google Scholar]
  22. Lastres P., Letamendía A., Zhang H., Rius C., Almendro N., Raab U., López L. A., Langa C., Fabra A., Letarte M. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol. 1996 Jun;133(5):1109–1121. doi: 10.1083/jcb.133.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lewis K. A., Gray P. C., Blount A. L., MacConell L. A., Wiater E., Bilezikjian L. M., Vale W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature. 2000 Mar 23;404(6776):411–414. doi: 10.1038/35006129. [DOI] [PubMed] [Google Scholar]
  24. López-Casillas F., Cheifetz S., Doody J., Andres J. L., Lane W. S., Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell. 1991 Nov 15;67(4):785–795. doi: 10.1016/0092-8674(91)90073-8. [DOI] [PubMed] [Google Scholar]
  25. López-Casillas F., Payne H. M., Andres J. L., Massagué J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol. 1994 Feb;124(4):557–568. doi: 10.1083/jcb.124.4.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. López-Casillas F., Wrana J. L., Massagué J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell. 1993 Jul 2;73(7):1435–1444. doi: 10.1016/0092-8674(93)90368-z. [DOI] [PubMed] [Google Scholar]
  27. Massagué J., Blain S. W., Lo R. S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000 Oct 13;103(2):295–309. doi: 10.1016/s0092-8674(00)00121-5. [DOI] [PubMed] [Google Scholar]
  28. Massagué J. Subunit structure of a high-affinity receptor for type beta-transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex. J Biol Chem. 1985 Jun 10;260(11):7059–7066. [PubMed] [Google Scholar]
  29. Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–791. doi: 10.1146/annurev.biochem.67.1.753. [DOI] [PubMed] [Google Scholar]
  30. Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597–641. doi: 10.1146/annurev.cb.06.110190.003121. [DOI] [PubMed] [Google Scholar]
  31. Mitchell E. J., Fitz-Gibbon L., O'Connor-McCourt M. D. Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-beta) receptors with different affinities for TGF-beta 1 and TGF-beta 2 are exhibited by human placental trophoblast cells. J Cell Physiol. 1992 Feb;150(2):334–343. doi: 10.1002/jcp.1041500217. [DOI] [PubMed] [Google Scholar]
  32. Moustakas A., Lin H. Y., Henis Y. I., Plamondon J., O'Connor-McCourt M. D., Lodish H. F. The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. J Biol Chem. 1993 Oct 25;268(30):22215–22218. [PubMed] [Google Scholar]
  33. O'Connor-McCourt M. D., Segarubu O., Grothe S., Tsang M. l., Weatherbee J. A. Analysis of the interaction between two TGF-beta-binding proteins and three TGF-beta isoforms using surface plasmon resonance. Ann N Y Acad Sci. 1995 Sep 7;766:300–302. doi: 10.1111/j.1749-6632.1995.tb26682.x. [DOI] [PubMed] [Google Scholar]
  34. ORNSTEIN L. DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY. Ann N Y Acad Sci. 1964 Dec 28;121:321–349. doi: 10.1111/j.1749-6632.1964.tb14207.x. [DOI] [PubMed] [Google Scholar]
  35. Pepin M. C., Beauchemin M., Plamondon J., O'Connor-McCourt M. D. Mapping of the ligand binding domain of the transforming growth factor beta receptor type III by deletion mutagenesis. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6997–7001. doi: 10.1073/pnas.91.15.6997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Piek E., Heldin C. H., Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 1999 Dec;13(15):2105–2124. [PubMed] [Google Scholar]
  37. Ponce-Castañeda M. V., Esparza-López J., Vilchis-Landeros M. M., Mendoza V., López-Casillas F. Murine betaglycan primary structure, expression and glycosaminoglycan attachment sites. Biochim Biophys Acta. 1998 May 19;1384(2):189–196. doi: 10.1016/s0167-4838(98)00033-8. [DOI] [PubMed] [Google Scholar]
  38. Reeves W. B., Andreoli T. E. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7667–7669. doi: 10.1073/pnas.97.14.7667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Roberts A. B., Sporn M. B. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993;8(1):1–9. doi: 10.3109/08977199309029129. [DOI] [PubMed] [Google Scholar]
  40. Sankar S., Mahooti-Brooks N., Centrella M., McCarthy T. L., Madri J. A. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem. 1995 Jun 2;270(22):13567–13572. doi: 10.1074/jbc.270.22.13567. [DOI] [PubMed] [Google Scholar]
  41. Seed B., Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A. 1987 May;84(10):3365–3369. doi: 10.1073/pnas.84.10.3365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Segarini P. R., Roberts A. B., Rosen D. M., Seyedin S. M. Membrane binding characteristics of two forms of transforming growth factor-beta. J Biol Chem. 1987 Oct 25;262(30):14655–14662. [PubMed] [Google Scholar]
  43. Shah M., Foreman D. M., Ferguson M. W. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet. 1992 Jan 25;339(8787):213–214. doi: 10.1016/0140-6736(92)90009-r. [DOI] [PubMed] [Google Scholar]
  44. Sharma K., Jin Y., Guo J., Ziyadeh F. N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996 Apr;45(4):522–530. doi: 10.2337/diab.45.4.522. [DOI] [PubMed] [Google Scholar]
  45. Sime P. J., Xing Z., Graham F. L., Csaky K. G., Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997 Aug 15;100(4):768–776. doi: 10.1172/JCI119590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Sojar H. T., Bahl O. P. Chemical deglycosylation of glycoproteins. Methods Enzymol. 1987;138:341–350. doi: 10.1016/0076-6879(87)38029-2. [DOI] [PubMed] [Google Scholar]
  47. Sun L., Chen C. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem. 1997 Oct 3;272(40):25367–25372. doi: 10.1074/jbc.272.40.25367. [DOI] [PubMed] [Google Scholar]
  48. Wang X. F., Lin H. Y., Ng-Eaton E., Downward J., Lodish H. F., Weinberg R. A. Expression cloning and characterization of the TGF-beta type III receptor. Cell. 1991 Nov 15;67(4):797–805. doi: 10.1016/0092-8674(91)90074-9. [DOI] [PubMed] [Google Scholar]
  49. Wrana J. L., Attisano L., Cárcamo J., Zentella A., Doody J., Laiho M., Wang X. F., Massagué J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992 Dec 11;71(6):1003–1014. doi: 10.1016/0092-8674(92)90395-s. [DOI] [PubMed] [Google Scholar]
  50. Ziyadeh F. N., Hoffman B. B., Han D. C., Iglesias-De La Cruz M. C., Hong S. W., Isono M., Chen S., McGowan T. A., Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8015–8020. doi: 10.1073/pnas.120055097. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES